Regeneron Pharmaceuticals Announces Data From Its Phase 3 OPTIMA Study Of Pasatru To Treat Fibrodysplasia Ossificans Progressiva Shows Efficacy In Stopping New Bone Growth; Trial Meets Primary Endpoint By Reducing 90% New Heterotopic Ossification Lesions

Loading news article.

Regeneron Pharmaceuticals Announces Data From Its Phase 3 OPTIMA Study Of Pasatru To Treat Fibrodysplasia Ossificans Progressiva Shows Efficacy In Stopping New Bone Growth; Trial Meets Primary Endpoint By Reducing 90% New Heterotopic Ossification Lesions | WAPE

Regeneron Pharmaceuticals Announces Data From Its Phase 3 OPTIMA Study Of Pasatru To Treat Fibrodysplasia Ossificans Progressiva Shows Efficacy In Stopping New Bone Growth; Trial Meets Primary Endpoint By Reducing 90% New Heterotopic Ossification Lesions

Article summary

Related companies

Comments —